Results of Phase Ii Study of Combined Immunotherapy With Rituximab Plus Lymphokine-Activated Killer Cells as Maintenance in Follicular Lymphoma Patients
Hematological Oncology - United Kingdom
doi 10.1002/hon.192_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley